Aratana Therapeutics to Present at the Jefferies 2015 Animal Health Summit

KANSAS CITY, Kan., March 19, 2015 /PRNewswire/ -- Aratana Therapeutics, Inc. (NASDAQ: PETX), a pet therapeutics company focused on the licensing, development and commercialization of innovative biopharmaceutical products for companion animals, today announced that it will present at the Jefferies 2015 Animal Health Summit to be held March 26, 2015, at the Jefferies Conference Center in New York.  

Steven St. Peter, M.D., President and Chief Executive Officer of Aratana Therapeutics, will provide an overview of the Company's business during his live presentation and will be available to participate in one-on-one meetings with investors who are registered to attend the conference.


Jefferies 2015 Animal Health Summit


Thursday, March 26, 2015


10:30 am (Eastern Time) 


The Jefferies Global Conference Center – Bowling Green


520 Madison Avenue, New York, NY 10022

The presentations will be webcast live and remain available for 30 days following the presentation.  To access the webcasts, please visit the investor relations section of the Aratana website at

About Aratana Therapeutics
Aratana Therapeutics is a pet therapeutics company focused on licensing, developing and commercializing innovative biopharmaceutical products for companion animals. Aratana believes that it can leverage the investment in the human biopharmaceutical industry to bring therapeutics to pets in a capital and time efficient manner. The company's pipeline includes therapeutic candidates targeting pain, inappetence, cancer, viral diseases, allergy and other serious medical conditions.  Aratana believes the development and commercialization of these therapeutics will permit veterinarians and pet owners to manage pets' medical needs safely and effectively, resulting in longer and improved quality of life for pets. For more information, please visit

For investor inquires:
Aratana Therapeutics, Inc.
Craig Tooman; (913) 353-1026
For media inquiries:
Tiberend Strategic Advisors, Inc.
Andrew Mielach; (212) 375-2694

To view the original version on PR Newswire, visit:

SOURCE Aratana Therapeutics, Inc.

print email rss